JPWO2020144697A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020144697A5
JPWO2020144697A5 JP2021539922A JP2021539922A JPWO2020144697A5 JP WO2020144697 A5 JPWO2020144697 A5 JP WO2020144697A5 JP 2021539922 A JP2021539922 A JP 2021539922A JP 2021539922 A JP2021539922 A JP 2021539922A JP WO2020144697 A5 JPWO2020144697 A5 JP WO2020144697A5
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
antibody fragment
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519341A (ja
JP7606706B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2020/050047 external-priority patent/WO2020144697A1/en
Publication of JP2022519341A publication Critical patent/JP2022519341A/ja
Publication of JPWO2020144697A5 publication Critical patent/JPWO2020144697A5/ja
Priority to JP2024213235A priority Critical patent/JP7788118B2/ja
Application granted granted Critical
Publication of JP7606706B2 publication Critical patent/JP7606706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539922A 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体 Active JP7606706B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213235A JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791808P 2019-01-13 2019-01-13
US62/791,808 2019-01-13
PCT/IL2020/050047 WO2020144697A1 (en) 2019-01-13 2020-01-13 Antibodies specific to human nectin-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213235A Division JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Publications (3)

Publication Number Publication Date
JP2022519341A JP2022519341A (ja) 2022-03-23
JPWO2020144697A5 true JPWO2020144697A5 (enExample) 2023-01-20
JP7606706B2 JP7606706B2 (ja) 2024-12-26

Family

ID=69701225

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539922A Active JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Country Status (9)

Country Link
US (1) US12545727B2 (enExample)
EP (1) EP3908372A1 (enExample)
JP (2) JP7606706B2 (enExample)
KR (1) KR20210117277A (enExample)
CN (2) CN118878685A (enExample)
AU (1) AU2020207664B2 (enExample)
CA (1) CA3125962A1 (enExample)
IL (1) IL284807B2 (enExample)
WO (1) WO2020144697A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240152879A (ko) 2022-02-28 2024-10-22 넥틴 테라퓨틱스 리미티드 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
WO2024240902A1 (en) 2023-05-23 2024-11-28 Fondazione per l'Istituto Oncologico di Ricerca Monospecific and bispecific antibodies and antibody-drug conjugates targeting nectin2 (cd112) and psma
WO2024240899A1 (en) 2023-05-23 2024-11-28 Universite De Geneve Dual targeting of psma and nectin2 in prostate cancer
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
KR20250161706A9 (ko) 2024-05-08 2026-02-03 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 항체 및 이의 용도
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도
KR20250175021A (ko) 2024-06-05 2025-12-16 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 인간화 항체 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
JP3490437B2 (ja) 1992-01-23 2004-01-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 単量体および二量体抗体フラグメント融合タンパク質
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69633175T2 (de) 1995-05-23 2005-08-11 Morphosys Ag Multimere proteine
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
EP1932857A1 (en) 2005-10-07 2008-06-18 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
PE20081456A1 (es) 2006-10-06 2008-11-27 Takeda Pharmaceutical Anticuerpo monoclonal contra nectina 2
WO2008126847A1 (ja) 2007-04-11 2008-10-23 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
PL2800196T3 (pl) 2011-12-27 2019-05-31 Lg Chemical Ltd Litowa bateria akumulatorowa i sposób jej wytwarzania
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA2997179A1 (en) * 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
AU2016323069A1 (en) 2015-09-14 2018-04-12 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
CN109071666B (zh) * 2016-03-01 2022-06-28 耶路撒冷希伯来大学伊森姆研究发展有限公司 人脊髓灰质炎病毒受体(pvr)特异性抗体
EP3448875A4 (en) 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
KR20240152879A (ko) 2022-02-28 2024-10-22 넥틴 테라퓨틱스 리미티드 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체

Similar Documents

Publication Publication Date Title
US12077583B2 (en) Antibodies specific to human NECTIN4
US11136392B2 (en) PD-1 immune modulating agents
RU2756275C2 (ru) Антитела, специфические к рецептору полиовируса (pvr) человека
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
JPWO2019215728A5 (enExample)
JP2019511212A5 (enExample)
JP2018532383A5 (enExample)
US12110337B2 (en) Anti-CD27 antibodies and uses thereof
US12545727B2 (en) Antibodies specific to human Nectin-2
HUE035865T2 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US11325976B2 (en) Anti-programmed death-ligand 1 (PD-L1) antibodies and therapeutic uses thereof
JP2023517794A (ja) 抗tnfr2抗体及びその使用
JPWO2020144697A5 (enExample)
RU2021118587A (ru) Антитела, специфичные в отношении нектина-2 человека
RU2020133629A (ru) Антитела, специфичные к нектину-4 человека
HK40060175A (en) Antibodies specific to human nectin-2
NZ745564B2 (en) Antibodies specific to human poliovirus receptor (pvr)